Skip to main
BMEA

BMEA Stock Forecast & Price Target

BMEA Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biomea Fusion Inc has made significant advancements in its drug development programs for diabetes and obesity, which are supported by promising Phase II results for icovamenib and the initiation of a Phase I trial for BMF-650. Financially, the company has demonstrated improved efficiency, with a narrowed net loss of $61.8 million and reduced R&D expenses, indicating a more manageable cost structure as it focuses on its core metabolic assets. The positive trajectory of clinical data, including durable glycemic benefits and favorable safety profiles, suggests a solid foundation for upcoming data readouts in 2026, bolstering the outlook for the company's stock.

Bears say

Biomea Fusion Inc. has reported a significant decrease in research and development expenses, from $27.2 million in Q3 2024 to $14.4 million in Q3 2025, which may raise concerns about the viability and progress of its drug candidate programs. Additionally, general and administrative expenses have also declined, from $6.8 million to $4.2 million, potentially indicating tightening operational budgets amid financial pressures. The reduction in price target from $16.00 to $12.00 reflects an overall negative sentiment regarding the company's financial outlook and the efficacy of its ongoing clinical trials for diabetes and obesity treatments.

BMEA has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biomea Fusion Inc (BMEA) Forecast

Analysts have given BMEA a Strong Buy based on their latest research and market trends.

According to 6 analysts, BMEA has a Strong Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biomea Fusion Inc (BMEA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.